OptiBiotix Health (OPTI) has entered into a three-year distribution agreement with SilvEXPO, to distribute and commercialise its CholBiome® products in Russia and Kazakhstan.
It grants SilvExpo non-exclusive distribution rights for OptiBiotix’s CholBiome® products, which contain the cholesterol and blood pressure reducing LPLDL® strain.
The Russian probiotics market alone is estimated at €340 million with a 10% annual growth, according to Euromonitor. SilvExpo experience in these markets is set to enable OptiBiotix to introduce the CholBiome® range of products into the chain of pharmacies in one of the largest Eastern European markets for probiotics.
Per Rehné, Commercial Director of OptiBiotix, commented: "We are pleased to announce this agreement which extends the sales channel of our CholBiome® products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality.”
“We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.”
The company said that it anticipates that the agreement “could produce revenues quickly”.
Follow News & Updates from OptiBiotix here: